Changes in the gut microbiome before rheumatoid arthritis is developed could provide a window of opportunity for preventative treatments, new research suggests.
Successful treatment of PP by daily subcutaneous (SC) administration of the LH-RH agonist D-Trp-6-LH-RH (Trp6) was reported (Kauli et al., ESPE 1983). After demonstration of its efficiency and ...